OSA

ProSomnus, Inc. Common Stock

OSA

Market cap $8.18M

Delisted

OSA was delisted on the 17th of April, 2024.

Back to rankings

Upgrade to unlock

Positive

Neutral

Negative

Sentiment 3-Months

Positive

Neutral 0%

Negative

ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript

ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023.

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call.

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA).

ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices.

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

See News Rankings